1887

Abstract

Cell-mediated immunity plays an important role in the host response against human cytomegalovirus (HCMV) infection. For the development of HCMV subunit vaccines it is essential to identify which HCMV proteins can induce protective immune responses in humans. We have studied the T cell proliferative responses to five HCMV proteins (IE1, IE2, pp71, gpUL18 and gB). These five proteins were produced using the maltose-binding protein (MBP) fusion protein system. T cell proliferative responses in 23 seropositive and six seronegative individuals were evaluated. None of the six seronegative individuals showed significant responses to any of the proteins. Of the 23 seropositive individuals, five responded to all five proteins, 14 responded to between one and four proteins and four responded to none of the proteins. The most commonly recognized proteins were gB (17/23, 74%) and IE2 (16/23, 70%). pp71 and IE1 were recognized by 10 of 23 (43%) individuals. Nine of 22 (41%) individuals tested responded to gpUL18, providing evidence that this protein is produced during infection. Our data indicate that a subunit vaccine composed of gB alone may not be sufficient to induce protective immunity in all individuals. The combination of two or three proteins may be more efficient as a potential vaccine.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-76-7-1603
1995-07-01
2021-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jgv/76/7/JV0760071603.html?itemId=/content/journal/jgv/10.1099/0022-1317-76-7-1603&mimeType=html&fmt=ahah

References

  1. Alp J. A., Allport T. D., Zanten J. V., Rodgers B., Sissons J. G. P., Borysiewicz L. K. 1991; Fine specificity of cellular immune responses in humans to human cytomegalovirus immediate-early 1 protein. Journal of Virology 65:4812–4820
    [Google Scholar]
  2. Alper C. A., Kruskall M. S., Marcus-Bagley D., Craven D. E., Katz A. J., Brink S. J., Dienstag J. L., Awdeh Z., Yunis E. J. 1989; Genetic prediction of nonresponse to hepatitis B vaccine. New England Journal of Medicine 321:708–712
    [Google Scholar]
  3. Balfour H. H., Welo P. K., Sachs G. W. 1976; Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplantation Proceedings 17:81
    [Google Scholar]
  4. Beck S., Barrell B. G. 1988; Human cytomegalovirus encodes a glycoprotein homologous to MHC class I antigens. Nature 331:269–272
    [Google Scholar]
  5. Borysiewicz L. K., Hickling J. C., Graham S., Sinclair J., Cranage M. P., Smith G. L., Sissons J. G. P. 1988; Human cytomegalovirus specific cytotoxic T cells: relative frequency of stage-specific CTL recognizing the 72kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. Journal of Experimental Medicine 168:919–932
    [Google Scholar]
  6. Britt W. J. 1991; Recent advances in the identification of significant human cytomegalovirus-encoded proteins. Transplantation Proceedings 23:64–69
    [Google Scholar]
  7. Browne H., Churcher M., Minson T. 1992; Construction and characterization of a human cytomegalovirus mutant with the UL18 (class I homolog) gene deleted. Journal of Virology 66:6784–6787
    [Google Scholar]
  8. Chicz R. M., Urban R. G., Gorga J. C., Vignali D. A. A., Lane W. S., Strominger R. L. 1993; Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. Journal of Experimental Medicine 178:27–47
    [Google Scholar]
  9. Davis M. G., Kenney S. C., Kamine J., Pagano J. S., Huang E. S. 1987; Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proceedings of the National Academy of Sciences, USA 84:8642–8646
    [Google Scholar]
  10. Del Val M., Schlicht H., Volkmer H., Messerle M., Reddehase M. J., Koszinowski U. H. 1991; Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. Journal of Virology 65:3641–3646
    [Google Scholar]
  11. Fujinami R. S., Nelson J. A., Walker L., Oldstone M. B. A. 1988; Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DRB chain: a means for graft rejection and immunosuppression. Journal of Virology 62:100–105
    [Google Scholar]
  12. Gilbert M. J., Riddell S. R., Greenberg P. D. 1993; Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. Journal of Immunology 67:3461–3469
    [Google Scholar]
  13. Greenberg P., Goodrich J., Riddell S. R. 1991a; Adoptive immunotherapy of human cytomegalovirus infection: potential role in protection from disease progression. Transplantation Proceedings 23:97–101
    [Google Scholar]
  14. Greenberg P. D., Reusser P., Goodrich J. M., Riddell S. R. 1991b; Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro. Annals of the New York Academy of Sciences 636:184–195
    [Google Scholar]
  15. Griffiths P. D., Grundy J. E. 1987; Molecular biology and immunology of cytomegalovirus. Biochemistry Journal 241:313–324
    [Google Scholar]
  16. Grundy J. E. 1991; Cytomegalovirus vaccines. In Vaccines and Immunotherapy pp 351–356 Edited by Cryzs J. S. J. New York: Pergamon Press;
    [Google Scholar]
  17. Ho M. 1990; Epidemiology of cytomegalovirus infections. Reviews of Infectious Diseases 12: Supplement 7S701–710
    [Google Scholar]
  18. John G., Scholl B.-C., Traupe B., Fleckenstein B. 1987; The two major structural phosphoproteins (pp65 and ppl50) of human cytomegalovirus and their antigenic properties. Journal of General Virology 68:1327–1337
    [Google Scholar]
  19. Jonjic S., Pavic I., Lucin P., Rukavina D., Koszinowski U. H. 1990; Efficacious control of cytomegalovirus infection after longterm depletion of CD8+ T lymphocytes. Journal of Virology 64:5457–5464
    [Google Scholar]
  20. Kniskern P. J., Miller W. J. 1992; Hepatitis B vaccines: blueprints for vaccines of the future. In Vaccines: New Approaches to Immunological Problems pp 177–204 Edited by Elliss R. W. Boston: Butterworth-Heinemann;
    [Google Scholar]
  21. Lindsley M. D., Torpey D. J. III, Rinaldo C. R. JR 1986; HLA-DR-restricted cytotoxicity of cytomegalovirus-infected monocytes mediated by Leu-3-positive T cells. Journal of Immunology 136:3045–3051
    [Google Scholar]
  22. Liu B., Stinski M. F. 1992; Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements. Journal of Virology 66:4434–4444
    [Google Scholar]
  23. Liu Y. N., Kari B., Gehrz R. C. 1988; Human immune response to major human cytomegalovirus glycoprotein complexes. Journal of Virology 62:1066–1070
    [Google Scholar]
  24. Liu Y.-N., Curtsinger J., Donahue P. R., Klaus A., Optiz G., Cooper J., Karr R. W., Bach F. H., Gehrz R. C. 1993; Molecular analysis of the immune response to human cytomegalovirus glycoprotein B. I. Mapping of HLA-restricted helper T cell epitopes on gp93. Journal of General Virology 74:2207–2214
    [Google Scholar]
  25. Maina C. V., Riggs P. D., Grandea A. G. I., Slatko B. E., Moran L. S., Tagliamonte J. A., McReynolds L. A., Guan C. 1988; A vector to express and purify foreign proteins in Escherichia coli by fusion to, and separation from, maltose binding protein. Gene 74:365–373
    [Google Scholar]
  26. Marshall G. S., Rabalais G. P., Stout G. G., Waldeyer S. L. 1992; Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. Journal of Infectious Disease 165:381–384
    [Google Scholar]
  27. Morel P. A., Chang H. J., Wilson J. W., Conte C., Saidman S. L., Bray J. D., Tweardy D. J. JR, Medsger T. A. 1994; Severe systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRwll allele. Human Immunology 40:101–110
    [Google Scholar]
  28. Plotkin S. A. 1991; Cytomegalovirus vaccine development - past and present. Transplantation Proceedings 23:85–89
    [Google Scholar]
  29. Plotkin S. A., Farquar J., Hornberger E. 1976; Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. Journal of Infectious Diseases 134:470–475
    [Google Scholar]
  30. Quinnan G. V. J., Burns W. H., Kirmani N., Rook A. H., Manischewitz J., Jackson L., Santos G. W., Saral R. 1984; HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infection. Reviews of Infectious Diseases 6:156–163
    [Google Scholar]
  31. Rammensee H. G., Falk K., Rotzschke O. 1993; MHC molecules as peptide receptors. Current Opinion in Immunology 5:35–44
    [Google Scholar]
  32. Rasmussen L. 1990; Immune response to human cytomegalovirus infection. Current Topics in Microbiology and Immunology 154:221–254
    [Google Scholar]
  33. Rasmussen L., Morris S., Wolitz R., Dowling A., Fessell J., Holodniy M., Merrigan T. 1994; Deficiency in antibody responses to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. Journal of Infectious Diseases 170:673–677
    [Google Scholar]
  34. Riddell S. R., Watanabe K. S., Goodrich J. M., Li C. R., Agha M. E., Greenberg P. D. 1992; Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238–241
    [Google Scholar]
  35. Spaete R. R. 1991; A recombinant subunit vaccine approach to HCMV vaccine development. Transplantation Proceedings 23:90–96
    [Google Scholar]
  36. Spaete R. R., Thayer R. M., Probert W. S., Masiarz F. R., Chamberlain S. H., Rasmussen L., Merigan T. C., Pachl C. 1988; Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 167:207–225
    [Google Scholar]
  37. Thomsen D. R., Stinski M. F. 1981; Cloning of the human cytomegalovirus genome as endonuclease Xbal fragments. Gene 16:207–216
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-76-7-1603
Loading
/content/journal/jgv/10.1099/0022-1317-76-7-1603
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error